跳至主要内容
临床试验/CTRI/2025/10/095792
CTRI/2025/10/095792招募中2/3 期

Clinical Study to Evaluate Efficacy and Safety of Zandu ultra power balm in subjects suffering from headache, cold, body ache, muscle pain and joint pain

Emami Ltd.1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2025年10月29日最近更新:

试验速览

阶段
2/3 期
状态
招募中
发起方
入组人数
30
试验地点
1
主要终点
2. Number and percentage of participants who report complete relief in

研究概览

简要总结

It is a clinical study to evaluate efficacy and safety of Zandu ultra power balm in subjects suffering from headache, cold, body ache, muscle pain and joint pain. The study will be carried out at 1-2 centres in India. There will be two cohorts. In cohort 1, subjects suffering from cold symptoms, headache and body ache will be recruited. In cohort 2, subjects suffering from muscle and joint pain will be recruited. In Cohort 1, subjects will be asked to apply Zandu Ultra Power balm on forehead, nose, paranasal sinuses area, throat and chest three times daily for 7 days. and in Cohort 2, subject will be asked to apply sufficient quantity of assigned product on the affected part two times daily for 30 days.

Cohort 1: In Primary objectives of the study will be to assess change in cold symptoms i.e. nasal block, cough, headache, sore throat, runny nose, body ache and number and percentage of participants who report complete relief in headache, cold and body ache. Secondary objectives of the study will be to assess satisfaction of the quality of sleep, requirement of rescue medications, skin patch test, global assessment for overall change by participants and by physician and adverse events, adverse drug reactions including vitals

 Cohort 2: Primary objective of the study will be to assess change in joint and muscle pain on VAS scale. Secondary objectives of the study will be to assess requirement of rescue medications, skin patch test, onset of action of Zandu ultra power balm as pain relief, duration of action of the Zandu ultra power balm as pain reliever, global assessment for overall change as assessed by participants and investigator and tolerability of study medications as assessed by participants and investigator on Baseline Visit, Visit1 (24hrs), Visit 2 (48hrs), Visit 3 (Day 3), Visit 4 (Day 7)

研究设计

研究类型
Interventional
分配方式
Na
盲法
None

入排标准

年龄范围
18.00 Year(s) 至 65.00 Year(s)(—)
性别
All

入选标准

  • Cohort 1:
  • Clinically diagnosed with common cold
  • Beginning of the symptoms of common cold in a minimum period of 24 hours and a maximum of 72 hours prior to baseline visit.
  • Willing to comply with all requirements of the study Cohort 2-
  • Participants suffering from neck and shoulder pain, sprains, strong knee pain, muscle pain, and joint pain
  • Subjects with pain on VAS scale greater than 40 mm
  • Subjects who willing to sign the written informed consent and ready to comply with the protocol requirement.

排除标准

  • 未提供

结局指标

主要结局

2. Number and percentage of participants who report complete relief in

时间窗: Baseline Visit, Visit1 (24hrs), Visit 2 (48hrs), Visit 3 Day 3, Visit4 Day 7

headache, cold and body ache

时间窗: Baseline Visit, Visit1 (24hrs), Visit 2 (48hrs), Visit 3 Day 3, Visit4 Day 7

Cohort 2

时间窗: Baseline Visit, Visit1 (24hrs), Visit 2 (48hrs), Visit 3 Day 3, Visit4 Day 7

Change in joint and muscle pain on VAS scale

时间窗: Baseline Visit, Visit1 (24hrs), Visit 2 (48hrs), Visit 3 Day 3, Visit4 Day 7

Cohort 1

时间窗: Baseline Visit, Visit1 (24hrs), Visit 2 (48hrs), Visit 3 Day 3, Visit4 Day 7

1. Change in cold symptoms i.e. nasal block, cough, headache, sore throat,

时间窗: Baseline Visit, Visit1 (24hrs), Visit 2 (48hrs), Visit 3 Day 3, Visit4 Day 7

runny nose, body ache

时间窗: Baseline Visit, Visit1 (24hrs), Visit 2 (48hrs), Visit 3 Day 3, Visit4 Day 7

次要结局

  • Cohort 1(1. Satisfaction of the quality of sleep)

研究者

发起方
Emami Ltd.
申办方类型
Other [Healthcare Industry]
责任方
Principal Investigator
主要研究者

Dr Priyanka Patil

Shree Sai Clinic

研究点 (1)

Loading locations...

相似试验